• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Conference on Radiological Protection of Patients in Diagnostic and Interventional Radiology, Nuclear Medicine and Radiotherapy, Mar 26-30, 2001, In Malaga, Spain >RADIOLOGICAL PROTECTION CONSIDERATIONS DURING THE TREATMENTOF GLIOBLASTOMA PATIENTS BY BORON NEUTRON CAPTURE THERAPYAT THE HIGH FLUX REACTOR IN PETTEN, THE NETHERLANDS
【24h】

RADIOLOGICAL PROTECTION CONSIDERATIONS DURING THE TREATMENTOF GLIOBLASTOMA PATIENTS BY BORON NEUTRON CAPTURE THERAPYAT THE HIGH FLUX REACTOR IN PETTEN, THE NETHERLANDS

机译：硼中子捕获治疗在荷兰滕滕的高通量反应器中治疗 r n成胶质细胞瘤患者期间的放射防护注意事项

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A clinical trial of Boron Neutron Capture Therapy (BNCT) for glioblastoma patients has been in progress at thernHigh Flux Reactor (HFR) at Petten since October 1997. The JRC (as licence holder of the HFR) must ensure thatrnradiological protection measures are provided. The BNCT trial is a truly European trial, whereby the treatmentrntakes place at a facility in the Netherlands under the responsibility of clinicians from Germany and patients arerntreated from several European countries. Consequently, radiological protection measures satisfy both Germanrnand Dutch laws. To respect both laws, a BNCT radioprotection committee was formed under the chairmanship ofrnan independent radioprotection expert, with members representing all disciplines in the trial. A special nuance ofrnBNCT is that the radiation is provided by a mixed neutron/gamma beam. The radiation dose to the patient is thusrna complex mix due to neutrons, gammas and neutron capture in boron, nitrogen and hydrogen, which, amongstrnothers, need to be correctly calculated in non-commercial and validated treatment planning codes. Furthermore,rndue to neutron activation, measurements on the patient are taken regularly after treatment. Further investigationsrnalong these lines, include, dose determination using TLDs and boron distribution measurements using on-linerngamma ray spectroscopy.
机译：自1997年10月以来，位于佩滕的高通量反应堆（HFR）一直在进行针对胶质母细胞瘤患者的硼中子捕获疗法（BNCT）的临床试验。JRC（作为HFR的许可证持有人）必须确保提供放射线防护措施。 BNCT试验是真正的欧洲试验，由德国临床医生负责在荷兰的一家工厂进行治疗，并从几个欧洲国家治疗患者。因此，放射防护措施既符合德国法律又符合荷兰法律。为了遵守这两项法律，在rnan独立放射防护专家的主持下成立了BNCT放射防护委员会，成员代表了该试验中的所有学科。 rnBNCT的一个细微差别是，辐射是由混合的中子/伽马射线提供的。由于中子，伽马射线和中子在硼，氮和氢中的俘获，因此对患者的辐射剂量是复杂的混合物，此外，还需要在非商业和经过验证的治疗计划法规中正确计算。此外，由于中子活化，在治疗后定期对患者进行测量。在这些方面的进一步研究包括使用TLD的剂量确定和使用线性伽玛射线光谱法进行硼分布测量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号